Miniatura

Fitxers

SanchisAC.pdf (1.58 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-07-31

Llicència de publicació

cc by (c) Cotes Sanchís et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173470

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1371/journal.pone.0235848

Resum

Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results: 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's tau = 0.613), lower in those subjects who received second-line (Kendall's tau = 0.539), especially with ramucirumab+CT (Kendall's tau = 0.413). Conclusion: This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines.

Matèries

Càncer d'estómac, Qualitat de vida, Metàstasi

Matèries (anglès)

Stomach cancer, Quality of life, Metastasis

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

COTES SANCHÍS, Almudena, GALLEGO, Javier, HERNANDEZ, Raquel, ARRAZUBI, Virginia, CUSTODIO, Ana, CANO, Juana maría, AGUADO, Gemma, MACIAS, Ismael, LOPEZ, Carlos, LÓPEZ, Flora, VISA, Laura, GARRIDO, Marcelo, MARTÍNEZ LAGO, Nieves, FERNÁNDEZ MONTES, Ana, LIMÓN, María luisa, AZKARATE, Aitor, PIMENTEL, Paola, REGUERA, Pablo, RAMCHANDANI, Avinash, CACHO, Juan diego, MARTÍN CARNICERO, Alfonso, GRANJA, Mónica, MARTÍN RICHARD, Marta, HERNÁNDEZ PÉREZ, Carolina, HURTADO, Alicia, SERRA, Òlbia, BUXO, Elvira, VIDAL TOCINO, Rosario, JIMÉNEZ FONSECA, Paula, CARMONA BAYONAS, Alberto. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. _PLoS One_. 2020. Vol. 15, núm. 7, pàgs. e0235848. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/173470]

Exportar metadades

JSON - METS

Compartir registre